vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and ZIPRECRUITER, INC. (ZIP). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $111.7M, roughly 1.5× ZIPRECRUITER, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 0.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -4.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ZipRecruiter, Inc. is an American employment marketplace for job seekers and employers.
ESPR vs ZIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $111.7M |
| Net Profit | — | $-835.0K |
| Gross Margin | — | 89.1% |
| Operating Margin | 50.6% | 3.6% |
| Net Margin | — | -0.7% |
| Revenue YoY | 143.7% | 0.6% |
| Net Profit YoY | — | 92.3% |
| EPS (diluted) | $0.32 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $111.7M | ||
| Q3 25 | $87.3M | $115.0M | ||
| Q2 25 | $82.4M | $112.2M | ||
| Q1 25 | $65.0M | $110.1M | ||
| Q4 24 | $69.1M | $111.0M | ||
| Q3 24 | $51.6M | $117.1M | ||
| Q2 24 | $73.8M | $123.7M | ||
| Q1 24 | $137.7M | $122.2M |
| Q4 25 | — | $-835.0K | ||
| Q3 25 | $-31.3M | $-9.8M | ||
| Q2 25 | $-12.7M | $-9.5M | ||
| Q1 25 | $-40.5M | $-12.8M | ||
| Q4 24 | — | $-10.8M | ||
| Q3 24 | $-29.5M | $-2.6M | ||
| Q2 24 | $-61.9M | $7.0M | ||
| Q1 24 | $61.0M | $-6.5M |
| Q4 25 | — | 89.1% | ||
| Q3 25 | — | 89.1% | ||
| Q2 25 | — | 89.3% | ||
| Q1 25 | — | 89.4% | ||
| Q4 24 | — | 89.6% | ||
| Q3 24 | — | 89.4% | ||
| Q2 24 | — | 89.5% | ||
| Q1 24 | — | 89.1% |
| Q4 25 | 50.6% | 3.6% | ||
| Q3 25 | -11.4% | -4.4% | ||
| Q2 25 | 8.6% | -5.9% | ||
| Q1 25 | -34.0% | -10.6% | ||
| Q4 24 | -6.4% | -3.6% | ||
| Q3 24 | -31.0% | -2.8% | ||
| Q2 24 | 3.5% | 7.6% | ||
| Q1 24 | 52.5% | -0.7% |
| Q4 25 | — | -0.7% | ||
| Q3 25 | -35.9% | -8.5% | ||
| Q2 25 | -15.4% | -8.5% | ||
| Q1 25 | -62.2% | -11.7% | ||
| Q4 24 | — | -9.7% | ||
| Q3 24 | -57.2% | -2.2% | ||
| Q2 24 | -83.9% | 5.7% | ||
| Q1 24 | 44.3% | -5.3% |
| Q4 25 | $0.32 | $-0.03 | ||
| Q3 25 | $-0.16 | $-0.11 | ||
| Q2 25 | $-0.06 | $-0.10 | ||
| Q1 25 | $-0.21 | $-0.13 | ||
| Q4 24 | $-0.14 | $-0.10 | ||
| Q3 24 | $-0.15 | $-0.03 | ||
| Q2 24 | $-0.33 | $0.07 | ||
| Q1 24 | $0.34 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $188.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $-77.2M |
| Total Assets | $465.9M | $569.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $188.0M | ||
| Q3 25 | $92.4M | $211.8M | ||
| Q2 25 | $86.1M | $203.5M | ||
| Q1 25 | $114.6M | $221.1M | ||
| Q4 24 | $144.8M | $218.4M | ||
| Q3 24 | $144.7M | $225.6M | ||
| Q2 24 | $189.3M | $271.7M | ||
| Q1 24 | $226.6M | $282.5M |
| Q4 25 | $-302.0M | $-77.2M | ||
| Q3 25 | $-451.4M | $-76.1M | ||
| Q2 25 | $-433.5M | $-65.9M | ||
| Q1 25 | $-426.2M | $-11.3M | ||
| Q4 24 | $-388.7M | $13.4M | ||
| Q3 24 | $-370.2M | $13.6M | ||
| Q2 24 | $-344.2M | $24.4M | ||
| Q1 24 | $-294.3M | $12.7M |
| Q4 25 | $465.9M | $569.7M | ||
| Q3 25 | $364.0M | $573.6M | ||
| Q2 25 | $347.1M | $592.4M | ||
| Q1 25 | $324.0M | $629.4M | ||
| Q4 24 | $343.8M | $664.1M | ||
| Q3 24 | $314.1M | $652.0M | ||
| Q2 24 | $352.3M | $665.3M | ||
| Q1 24 | $373.1M | $662.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $7.7M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.8% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $9.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $7.7M | ||
| Q3 25 | $-4.3M | $2.6M | ||
| Q2 25 | $-31.4M | $10.5M | ||
| Q1 25 | $-22.6M | $-9.9M | ||
| Q4 24 | $-35.0M | $12.5M | ||
| Q3 24 | $-35.3M | $9.3M | ||
| Q2 24 | $-7.2M | $21.9M | ||
| Q1 24 | $53.8M | $2.0M |
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | — | $-10.2M | ||
| Q4 24 | — | $12.0M | ||
| Q3 24 | $-35.5M | $9.2M | ||
| Q2 24 | $-7.3M | $21.7M | ||
| Q1 24 | $53.8M | $1.9M |
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 9.1% | ||
| Q1 25 | — | -9.3% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | -68.7% | 7.8% | ||
| Q2 24 | -9.9% | 17.6% | ||
| Q1 24 | 39.0% | 1.6% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.3% | 0.2% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.12× | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
ZIP
| License | $84.3M | 75% |
| Services | $27.4M | 25% |
